Ovarian Granulosa-Stromal Tumor clinical trials at University of California Health
1 research study open to eligible people
open to eligible females ages 18 years and up
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.